Kuwait vs Solomon Islands: Statin use vs. average non-HDL cholesterol levels
Kuwait
3.7
in 2018
Solomon Islands
3.7
in 2018
Kuwait rank
12th
Solomon Islands rank
12th
Statin use vs. average non-HDL cholesterol levels over time
- Kuwait
- Solomon Islands
How they compare
Kuwait currently reports 3.7 against 3.7 in Solomon Islands, a difference of 0.
The two have swapped places 1 time across 39 shared years of data; in 1980 it was Kuwait ahead.
Kuwait ranks 12th and Solomon Islands ranks 12th of 191 countries.
Kuwait has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Kuwait | Solomon Islands | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 4.28 | 3.32 | 0.96 | Kuwait |
| 1990s | 4.18 | 3.45 | 0.73 | Kuwait |
| 2000s | 4.01 | 3.52 | 0.49 | Kuwait |
| 2010s | 3.79 | 3.62 | 0.1667 | Kuwait |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Kuwait or Solomon Islands?
- Kuwait, at 3.7 against 3.7 in Solomon Islands as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Kuwait and Solomon Islands?
- 0, with Kuwait ahead.
- How many years of comparable data are there for Kuwait and Solomon Islands?
- 39 years are reported by both, from 1980 to 2018.
- How do Kuwait and Solomon Islands rank globally for statin use vs. average non-hdl cholesterol levels?
- Kuwait ranks 12th and Solomon Islands ranks 12th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.